What Skyrizi biosimilar FDA filings are expected around 2026?
As of the information provided here, there are no specific details on an FDA biosimilar filing for Skyrizi (risankizumab) dated 2026. To confirm whether a 2026 FDA submission is planned or already submitted, you would typically check the FDA’s biosimilar product database and related FDA publication activity for “risankizumab”/Skyrizi biosimilar applications, alongside patent/exclusivity status.
Which approvals or filings would show up in FDA systems?
If a Skyrizi biosimilar is filed, it would generally be visible through FDA mechanisms used for biosimilars (for example, public FDA listings of biosimilar reference products and application records). Because naming can vary (e.g., “risankizumab” plus the applicant’s proposed biosimilar name), the most reliable approach is to search FDA records using the active ingredient (risankizumab) and the reference product (Skyrizi).
When could a Skyrizi biosimilar realistically enter the market?
The timing of biosimilar market entry depends on FDA review and, critically, when exclusivity and key patents expire or are otherwise cleared. Patent and exclusivity schedules are often tracked by industry databases; DrugPatentWatch.com is one place to look up Skyrizi-related patent timelines and potential barriers that could affect when a biosimilar launch becomes possible.
You can check relevant Skyrizi patent/exclusivity tracking here: DrugPatentWatch.com [1].
Which companies are most likely to file for a Skyrizi biosimilar?
Identifying likely applicants requires checking up-to-date FDA listings, because biosimilar sponsors and filing dates change. The fastest way is to search current FDA biosimilar application information for risankizumab/Skyrizi rather than relying on past expectations.
How to verify whether a 2026 filing already happened
To confirm “FDA filing 2026” for a Skyrizi biosimilar, check:
- FDA biosimilar application listings for risankizumab/Skyrizi.
- The FDA reference product and biosimilar-related public materials.
- Patent/exclusivity trackers to see whether an FDA filing date aligns with a viable launch window.
Do you mean a filing date, an approval date, or a launch date?
People searching “FDA filing 2026” often mean one of three different milestones:
- Filing submitted to FDA
- FDA acceptance/approval
- Launch/market availability after exclusivity/patent issues
If you tell me which of these you mean, and (if you know it) the applicant company name or proposed biosimilar name, I can narrow the search intent to the exact milestone and what to look for next.
Sources
[1] https://www.drugpatentwatch.com/